Researchers at McGill University Health Centre’s Research Institute have developed an innovative “mini-heart” on a chip, a three-dimensional model that mimics the beating of a human heart. This groundbreaking model utilizes blood cells from patients with dilated cardiomyopathy (DCM), a serious heart condition that often leads to heart transplants.
The creation of this patient-specific 3D heart-on-a-chip aims to shed light on the mechanisms underlying DCM, expedite the testing of new treatments, and potentially revolutionize personalized medicine by evaluating how an individual’s heart tissue responds to various therapies.
Lead author of the study, Ali Mousavi, highlights the significance of this advancement, stating, “With this new patient-derived model, we can replicate aspects of an individual’s heart disease outside the body, paving the way for personalized treatments.” Dr. Renzo Cecere, a key figure in the project, emphasizes the model’s ability to closely mimic human heart behavior, offering hope for more effective treatments and a reduction in the need for heart transplants.
Dilated cardiomyopathy is characterized by an enlarged and weakened heart, making advancements in research and treatment crucial. The heart-on-a-chip technology has evolved over the past decade, with this model standing out for its use of patient-derived cells, reprogrammed into heart muscle cells that form a beating “mini-heart.”
Comparative analysis with a model created from cells of a healthy participant revealed distinctive differences in structure, contractions, beating patterns, calcium activity, and molecular characteristics. These findings demonstrate the potential of the model to replicate key features of DCM and provide personalized insights into heart disease.
This innovative approach holds promise for advancing our understanding of heart conditions and developing tailored treatments for patients.
Keyphrase: heart-on-a-chip technology
